The Synthetic Peptide CIGB-300 Inhibits NF-κB Translocation Affecting the Survival and Chemoresistance of NSCLC Cell Lines

Article

Summary *

The CK2 is a Ser/Thr kinase that has been historically associated with cancer. It is involved in cellproliferation, survival and apoptosis by modulating diverse signaling pathways, including Wnt and NF-kBamong the most relevant. CIGB-300 is a synthetic antitumor peptide with a novel mechanism of action, since it is capable of binding to CK2 substrates thus preventing the enzyme activity. NF-kB activation can reducechemotherapy efficiency in lung cancer. We have determined that CIGB-300 inhibits NF-kB (p65) nucleartranslocation. Based on this evidence, we hypothesize that supplementing cisplatin with CIGB-300 wouldimprove the treatment efficiency. Also, CIGB-300 alters the ability of lung cancer cells to grow in a threedimensional spheroid model. Information provided by the agent in SIGEVA